Table 3.
SVR rates for the different treatment options in hepatitis C patients with (mainly compensated) cirrhosis
| Treatment combination | Duration, weeks | Genotype |
|||
|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | ||
| SOF + R | 12 | 83–94 (TN) | 34 | 43 | |
| SOF + R | 16 | 87 | |||
| SOF + R | 24 | 100 | 60 (TE)-92 (TN) | 100 | |
| SOF + SMV ± R | 12/24 | 83 (w/o R) | 100 | ||
| SOF + DCV ± R | 12 | 92 | 83–89 | ||
| SOF + DCV ± R | 24 | 97 | |||
| SOF + LDV + R | 12 | 96 | |||
| SOF + LDV | 24 | 98 | 93–96 | ||
| SOF + LDV + R | 24 | 100 | |||
| PTV/r + OMV + DSV | 12 | 100 (1b) | |||
| PTV/r + OMV + DSV + R | 12 | 92 | |||
| PTV/r + OMV + DSV + R | 24 | 96 | |||
| PTV/r + OMV + R | 12/24 | 96–100 | |||
TN = Treatment-naïve; TE = treatment-experienced; SOF = sofosbuvir; SMV = simeprevir; R = ribavirin; DCV = daclatasvir; LDV = ledipasvir; PTV/r = paritaprevir/ritonavir; OMV = ombitasvir; DSV = dasabuvir.